Anthos Therapeutics is Developing a Hemostasis-Sparing Anticoagulant to Reduce the Hazard of Bleeding

Earlier this year, BioSpace tallied up the hottest U.S. biotech start-ups in their NextGen Bio Class of 2020 – Anthos Therapeutics was ranked #2. Anthos focuses on developing drugs for cardiovascular disease, especially for high-risk patients. Their goal? To develop next-generation anticoagulants that don’t have the bleeding risks current blood thinners have. Their lead drug is also long acting, meaning patients may only need to take it monthly versus daily.